QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) will highlight its transfusion medicine portfolio at the AABB 2025 Annual Meeting on Oct 16–17, 2025, following the FDA approval of the MTS™ DAT Card.

The MTS DAT Card completes the company's gel-based direct antiglobulin testing solution and, when paired with the ORTHO VISION™ Platform, offers column agglutination technology with software features like reflex testing and as-needed quality control to speed and standardize transfusion decisions.

Planned activities include education sessions on Rh(D) antigen and DARA interference, poster data on IgG/C3 detection and instrumentation reliability, and product demos of ORTHO VISION Max Swift, ORTHO VISION Swift (noting 98% uptime), and ORTHO CONNECT lab management software.

Positive

• FDA approval of MTS DAT Card for direct antiglobulin testing
• MTS DAT Card completes gel-based solution when paired with ORTHO VISION
• ORTHO VISION Swift reports 98% uptime, supporting lab reliability

Negative

• None.

Insights

Transfusion Medicine Product Strategist

FDA approval of the MTS™ DAT Card plus ORTHO VISION platform strengthens QuidelOrtho's lab automation and DAT offerings for transfusion decisions.

QuidelOrtho pairs a newly FDA-approved MTS™ DAT Card with its ORTHO VISION™ platform to deliver a gel-based direct antiglobulin testing workflow. The combination adds a gel-card DAT into an automated system that includes reflex testing and as-needed quality control, which can shorten time-to-result and standardize testing in high-volume transfusion laboratories.

The near-term impact depends on lab adoption, instrument connectivity, and procurement cycles. Performance claims such as 98% uptime for the ORTHO VISION Swift Analyzer and poster data on gel-card reliability support operational benefits, but adoption hinges on labs validating the kit, IT/middleware integration, and purchasing timelines following the Oct. 16, 2025 approval.

Watch for customer validation studies, rollout cadence for the MTS DAT Card across ORTHO VISION instruments, and published comparative performance metrics at AABB 2025 and in subsequent months. Expect procurement and validation activity to unfold over the next several quarters as labs evaluate integration and workflow gains.

FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine

SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The company's participation coincides with the recent FDA approval of its Micro Typing Systems (MTS) DAT Card and the continued expansion of its comprehensive direct antiglobulin testing and immunohematology portfolio.

The MTS DAT Card completes QuidelOrtho's gel-based solution for direct antiglobulin testing. When paired with the ORTHO VISION™ Platform, it combines proven column agglutination technology with advanced software capabilities – including reflex testing and as-needed quality control – to help laboratories deliver faster, more reliable results for patients who depend on timely transfusion decisions.

"The AABB Annual Meeting brings together the world's foremost leaders in blood and biotherapies," said Michelle Mullens, Global Product Manager, Portfolio Solutions Transfusion Medicine, at QuidelOrtho. "Our participation reinforces our dedication to driving innovation that advances laboratory performance and enhances efficiency, helping to improve patient outcomes worldwide."

Featured education sessions

• Sunday, 10:00–10:30 a.m. PT
  Missing Formula: The Challenging World of Rh(D) Antigen
  Sue T. Johnson, MSTM, MLS(ASCP)SBB^CM
  An in-depth look at the complexities of Rh(D) antigen identification and its implications for transfusion safety.
• Monday, 11:40 a.m.–12:10 p.m. PT
  Identifying the Imposter: How ID-MTS Gel Test Typing Can Help Blood Banks with DARA Patients
  Lehang Dingh, MLS(ASCP)SBB^CM
  Explore how gel testing can help distinguish true antibodies from drug interference in patients treated with daratumumab.
• Monday, 1:45–2:15 p.m. PT
  Type & Seek: Solution to the Patient Puzzle
  Shane Grimsley, DipRCPath, FBBTS, Senior Clinical Scientist, IBGRL
  Learn strategies for resolving complex serological cases using advanced immunohematology techniques.

Poster presentations

• Evaluation of a Gel Card Being Designed for the Detection of IgG and C3
  
  
• Reliability of Instrumentation for Immunohematology Testing in the Transfusion Medicine Laboratory

These posters offer insights into performance and reliability metrics that support confident decision-making in the lab.

Product demonstrations

• ORTHO VISION™ Max Swift Analyzer
  Max Capacity. Max Efficiency.
  Built for high-throughput labs, the ORTHO VISION Max Swift Analyzer delivers speed, reliability and walkaway automation with expanded capacity for samples and reagents.
• ORTHO VISION™ Swift Analyzer
  Automation. Precision. Confidence.
  Simplifies transfusion testing with 98% uptime and consistent, high-quality results powered by ID-MTS™ Gel Test technology.
• ORTHO CONNECT™ Lab Management Software
  Centralized Workflow Automation.
  Supports lab networks with middleware that streamlines operations, addresses staffing challenges and helps meet compliance demands.

Learn more and register

Explore the full agenda and secure your spot: https://cvent.me/bA4rgD?utm_source=webmax&utm_campaign=aabb25&utm_medium=media&utm_term=register-now&RefId=media

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact: Juliet Cunningham Vice President, Investor Relations IR@QuidelOrtho.com

Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications Media@QuidelOrtho.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-showcases-leadership-in-transfusion-medicine-at-aabb-2025-302587015.html

SOURCE QuidelOrtho Corporation

FAQ

What did QuidelOrtho (QDEL) announce at AABB 2025 on Oct 16–17, 2025?

QuidelOrtho showcased its transfusion medicine portfolio and highlighted the FDA approval of the MTS DAT Card paired with ORTHO VISION.

How does the FDA-approved MTS DAT Card affect QuidelOrtho's product offering (QDEL)?

The MTS DAT Card completes QuidelOrtho's gel-based direct antiglobulin testing lineup when used with ORTHO VISION.

Which ORTHO VISION systems will QuidelOrtho demo at AABB 2025 and what is their benefit?

Demos include ORTHO VISION Max Swift and ORTHO VISION Swift, offering high-throughput automation and reported 98% uptime for consistent results.

What clinical topics did QuidelOrtho present at AABB 2025 relevant to transfusion safety (QDEL)?

Sessions covered Rh(D) antigen identification, distinguishing drug interference in DARA patients, and resolving complex serological cases.

Will QuidelOrtho (QDEL) present data supporting MTS or instrumentation reliability at AABB 2025?

Yes — poster presentations include evaluation of a gel card for IgG and C3 detection and instrumentation reliability for immunohematology testing.